RESUMEN
BACKGROUND: Escherichia coli is the most common cause of bacteremia in high-income countries. To enable the development and implementation of effective prevention strategies, a better understanding of the current epidemiology of invasive E. coli infections is needed. METHODS: A systematic review of literature published between 1 January 2007 and 31 March 2018 on the burden and epidemiology of E. coli bacteremia in populations that include adults in high-income countries was conducted. Meta-analysis was performed for descriptive purposes. RESULTS: During the studied time interval, the estimated incidence rate of E. coli bacteremia was 48 per 100 000 person-years, but this increased considerably with age: rates per 100â 000 person-years wereâ >100 in 55-to-75-year-olds andâ >300 in 75-to-85-year-olds. Overall, E. coli accounted for 27% of documented bacteremia episodes: 18% if hospital acquired, 32% if community-onset healthcare associated, and 33% if community acquired. The estimated case fatality rate was 12%. Approximately 44% of episodes were community acquired, 27% community-onset healthcare associated, and 27% hospital acquired. Urinary tract infection (UTI) was the primary source for 53% of episodes. CONCLUSIONS: This systematic review confirms the substantial burden of E. coli bacteremia in older adults and justifies the implementation of community-level programs to prevent E. coli bacteremia and ideally UTI in this age group.
Asunto(s)
Bacteriemia , Infecciones Comunitarias Adquiridas , Infecciones por Escherichia coli , Infecciones Urinarias , Anciano , Bacteriemia/epidemiología , Infecciones Comunitarias Adquiridas/epidemiología , Escherichia coli , Infecciones por Escherichia coli/epidemiología , Humanos , Infecciones Urinarias/epidemiologíaRESUMEN
There is an increasing incidence of infectious complications caused by extraintestinal pathogenic Escherichia coli (ExPEC) after transrectal ultrasound-guided prostate needle biopsy (TRUS-PNB), and a need for prophylaxis methods effective against associated antibiotic-resistant organisms. We aimed to identify the O-serotypes of ExPEC isolates collected in a sample of 60 patients with invasive ExPEC disease (IED) after TRUS-PNB, by serotype-specific agglutination and polymerase chain reaction (PCR) assays. The prevalence of O-serotypes included in a tetravalent ExPEC vaccine was 38.3% by agglutination and 46.7% by PCR, while the prevalence of O-serotypes included in a decavalent vaccine was 58.3% and 73.3%, respectively. Therefore, compared to the tetravalent vaccine, the decavalent vaccine would theoretically provide coverage for serotypes carried by a higher proportion of circulating ExPEC in patients undergoing TRUS-PNB, including a high proportion of antibiotic-resistant organisms.
Asunto(s)
Infecciones por Escherichia coli , Sepsis , Infecciones Urinarias , Sistema Urinario , Biopsia con Aguja , Escherichia coli , Humanos , Masculino , Próstata/diagnóstico por imagen , Ultrasonografía IntervencionalRESUMEN
The efficacy and safety of artemether-lumefantrine for the treatment of malaria in nonimmune populations are not well defined. In this study, 165 nonimmune patients from Europe and non-malarious areas of Colombia with acute, uncomplicated falciparum malaria or mixed infection including P. falciparum were treated with the six-dose regimen of artemether-lumefantrine. The parasitologic cure rate at 28 days was 96.0% for the per protocol population (119/124 patients). Median times to parasite clearance and fever clearance were 41.5 and 36.8 hours, respectively. No patient had gametocytes after Day 7. Treatment was well tolerated; most adverse events were mild to moderate and seemed to be related to malaria. There were few serious adverse events, none of which were considered to be drug-related. No significant effects on ECG or laboratory parameters were observed. In conclusion, the six-dose regimen of artemether-lumefantrine was effective and well tolerated in the treatment of acute uncomplicated falciparum malaria in nonimmune patients.
Asunto(s)
Antimaláricos/farmacocinética , Antimaláricos/uso terapéutico , Artemisininas/farmacocinética , Artemisininas/uso terapéutico , Etanolaminas/farmacocinética , Etanolaminas/uso terapéutico , Fluorenos/farmacocinética , Fluorenos/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Enfermedad Aguda , Adolescente , Adulto , Anciano , Animales , Antimaláricos/efectos adversos , Antimaláricos/normas , Combinación Arteméter y Lumefantrina , Artemisininas/efectos adversos , Artemisininas/normas , Combinación de Medicamentos , Etanolaminas/efectos adversos , Etanolaminas/normas , Femenino , Fluorenos/efectos adversos , Fluorenos/normas , Humanos , Masculino , Persona de Mediana Edad , Parasitemia/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/aislamiento & purificación , Factores de Tiempo , Viaje , Resultado del TratamientoRESUMEN
BACKGROUND: The six-dose regimen of artemether-lumefantrine (AL) is now considered the gold standard for the treatment of uncomplicated Plasmodium falciparum malaria. There are few reports evaluating co-artemether in very young Nigerian infants and children. Results of the evaluation of the six-dose regimen in very young infants and children in Nigeria are presented in this report. METHODS: As part of a larger African study, this open label, non-comparative trial, assessed the efficacy and safety of six-dose regimen of AL tablets in 103 Nigerian infants and children weighing between five and 25 kg suffering from acute uncomplicated malaria. Treatment was administered under supervision over three days with children as in-patients. 12-lead ECG tracings were taken pre-treatment and at day 3. RESULTS: Ninety-three infants and children completed the study as stipulated by the protocol. Mean fever and parasite clearance times for the intent to treat population (ITT) were 24.9 h +/- (1.28) and 26 h +/- (4.14) and the corresponding figures for the per-protocol population (PP) were 19.24 h +/- 13.9 and 25.62 h +/- 11.25 respectively. Day 14 cure rates for the ITT and PP were 95.1% and 100% respectively while day 28 cure rates were 91.3% and 95.7% respectively. The overall PCR corrected day 28 cure rate was 95.1% for the ITT. The six-dose regimen of AL was well tolerated with no drug-related serious adverse events. Although six patients recorded a QTc prolongation of > 60 ms on D3 over D0 recording, no patient recorded a QTc interval > 500 ms. CONCLUSION: The six-dose regimen of AL tablets is safe and effective for the treatment of acute uncomplicated malaria in Nigerian infants and children weighing between five and 25 kg. TRIAL REGISTRATION: NCT00709969.
Asunto(s)
Artemisininas/efectos adversos , Artemisininas/uso terapéutico , Etanolaminas/efectos adversos , Etanolaminas/uso terapéutico , Fluorenos/efectos adversos , Fluorenos/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Animales , Combinación Arteméter y Lumefantrina , Sangre/parasitología , Niño , Preescolar , Combinación de Medicamentos , Femenino , Fiebre , Humanos , Lactante , Masculino , Nigeria , Plasmodium falciparum/efectos de los fármacos , Factores de Tiempo , Resultado del TratamientoRESUMEN
Patient data from eight clinical trials were pooled and analyzed to study the efficacy and safety of the six-dose versus four-dose regimen of artemether-lumefantrine (coartemether; Coartem) in children weighing 5-25 kg. A total of 544 patients with uncomplicated P. falciparum malaria (six-dose: 343; four-dose: 201), matched for demographic and baseline characteristics and individual coartemether doses were included in the analysis. Analysis of day 28 cure rate based on the intention-to-treat and evaluable populations yielded corrected cure rates for the six-dose regimen of 93% and 96% compared with 61% and 76%, respectively, for the four-dose regimen (P < 0.0001 for both comparisons). Similarly high cure rates were achieved with the six-dose regimen in non-immune infants weighing as little as 5 kg. The six- and four-dose regimens were equally well tolerated. The main finding of this analysis is that the six-dose regimen of coartemether is safe and more efficacious than the four-dose regimen in children.
Asunto(s)
Antimaláricos/uso terapéutico , Artemisininas/uso terapéutico , Etanolaminas/uso terapéutico , Fluorenos/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Animales , Antimaláricos/administración & dosificación , Antimaláricos/efectos adversos , Antimaláricos/normas , Arteméter , Artemisininas/administración & dosificación , Artemisininas/efectos adversos , Artemisininas/normas , Peso Corporal , Niño , Preescolar , Ensayos Clínicos como Asunto , Esquema de Medicación , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Electrocardiografía/efectos de los fármacos , Etanolaminas/administración & dosificación , Etanolaminas/efectos adversos , Etanolaminas/normas , Femenino , Fiebre , Fluorenos/administración & dosificación , Fluorenos/efectos adversos , Fluorenos/normas , Humanos , Lactante , Estadios del Ciclo de Vida/efectos de los fármacos , Lumefantrina , Masculino , Factores de TiempoRESUMEN
To demonstrate the superiority of the six-dose over the four-dose regimen of artemether-lumefantrine (co-artemether, Coartem) in patients >12 years, data from 11 randomized clinical trials were pooled and analyzed. A total of 1368 patients with uncomplicated Plasmodium falciparum malaria (six-dose: 598; four-dose: 770) were included in the analysis, together with 717 patients treated with comparators. Analysis of the 28-day cure rate based on the ITT and evaluable populations yielded corrected cure rates for the six-dose regimen of 87% and 97% compared with 74% and 87%, respectively, with the four-dose regimen (P<0.0001, for both comparisons). For mefloquine/artesunate, the most frequently used comparator, cure rates were 87% and 99%, respectively. The six-dose regimen was well tolerated and not markedly different to the four-dose regimen. The main finding of our analysis is that the six-dose regimen of co-artemether is more effective than the four-dose regimen in adolescents and adults without compromising safety.
Asunto(s)
Antimaláricos , Artemisininas , Fluorenos , Malaria Falciparum/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Sesquiterpenos , Adolescente , Adulto , Anciano , Animales , Antimaláricos/administración & dosificación , Antimaláricos/efectos adversos , Antimaláricos/uso terapéutico , Combinación Arteméter y Lumefantrina , Artemisininas/administración & dosificación , Artemisininas/efectos adversos , Artemisininas/uso terapéutico , Combinación de Medicamentos , Etanolaminas , Femenino , Fluorenos/administración & dosificación , Fluorenos/efectos adversos , Fluorenos/uso terapéutico , Humanos , Malaria Falciparum/parasitología , Masculino , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Sesquiterpenos/administración & dosificación , Sesquiterpenos/efectos adversos , Sesquiterpenos/uso terapéutico , Resultado del TratamientoRESUMEN
Approximately one million children die from malaria each year. A recently approved artemisinin-based tablet, Coartem (co-artemether), comprising artemether 120 mg plus lumefantrine 20 mg, given in four doses, provides effective antimalarial treatment for children in many sub-Saharan countries. However, this regimen is considered insufficient for non-immune infants and in areas where multidrug-resistant Plasmodium falciparum predominates. This open-label study assessed the efficacy and safety of co-artemether administered to 310 African children weighing 5-25 kg, with acute, uncomplicated falciparum malaria. Six doses of co-artemether were given over 3 days, with follow-up at 7, 14 and 28 days. Treatment rapidly cleared parasitemia and fever. The overall 28-day cure rate was 86.5%, and 93.9% when corrected by PCR for reinfection. Cure rates at 7 and 14 days exceeded 97.0% (uncorrected) and, on day 28, were similar in infants (5-<10 kg) previously exposed to malaria infection (partially immune: 88.6% uncorrected; 93.3% corrected), and in those who were non-immune (82.5% uncorrected; 95.0% corrected). Adverse events were mostly mild. There was no electrocardiographic evidence of cardiotoxicity. The co-artemether six-dose regimen, treating acute uncomplicated falciparum malaria in African children, achieved rapid parasite clearance and a high cure rate. Treatment was generally safe and well tolerated.
Asunto(s)
Antimaláricos/administración & dosificación , Artemisininas/administración & dosificación , Fluorenos/administración & dosificación , Malaria Falciparum/tratamiento farmacológico , Sesquiterpenos/administración & dosificación , Enfermedad Aguda , Antimaláricos/efectos adversos , Combinación Arteméter y Lumefantrina , Artemisininas/efectos adversos , Niño , Preescolar , Esquema de Medicación , Combinación de Medicamentos , Etanolaminas , Femenino , Fluorenos/efectos adversos , Frecuencia Cardíaca , Pruebas Hematológicas , Humanos , Lactante , Kenia/epidemiología , Malaria Falciparum/epidemiología , Malaria Falciparum/inmunología , Masculino , Nigeria/epidemiología , Recuento de Huevos de Parásitos , Sesquiterpenos/efectos adversos , Distribución por Sexo , Tanzanía/epidemiología , Factores de Tiempo , Resultado del TratamientoRESUMEN
OBJECTIVE: To assess the efficacy of a continuous-combined transdermal patch (estradiol/ norethisterone acetate [E(2)/NETA] 25/125; Estragest TTS, Novartis, Basel, Switzerland) in the reduction of bone loss in postmenopausal women. DESIGN: In a 96-week, double-blind, randomized, multicenter, parallel study, 124 healthy women with an intact uterus more than 4 years after menopause received either transdermal continuous-combined E(2)/NETA (0.025/0.125 mg/day) or placebo patch for 24 treatment cycles; diet was normalized for calcium intake. Lumbar spine bone mineral density (BMD) ranged from 0.969 to 0.805 g/cm2 with a mean annual BMD decrement ranging from 3% to 8% within the last 24 months. BMD at lumbar spine L(2)-L(4) (postero-anterior) and femur were assessed by dual energy x-ray absorptiometry after 6, 12, and 24 cycles. Efficacy variables included measurement of biochemical markers of bone turnover (3, 6, 12, and 24 months). RESULTS: BMD at lumbar spine was significantly higher at all time points in the E(2)/NETA group than in the placebo group (P < 0.0001). Significant increases in BMD (P < 0.0008) from baseline were observed at all sites after 24 months in the E(2)/NETA group compared with placebo, which demonstrated a decrease from baseline. At endpoint, statistically significant decrements in the values of bone remodeling markers were observed (P < 0.05) with E(2)/NETA. CONCLUSIONS: E(2)/NETA 25/125 Estragest TTS was more effective than placebo in reducing the activation frequency of bone remodeling and in preventing bone loss at the spine and hip. Effects on the hip were similar to those observed for higher doses of estrogen.